Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
Online dating has revolutionized dating by creating more opportunities to meet partners than ever before.
Read Full NewsPatients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
1.
Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study
2.
New methods show how fast breast cancers grow and how surgery delays affect cancer staging
3.
Some low-grade prostate cancers carry higher risks than biopsy suggests
4.
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer
5.
Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs
1.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
2.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
3.
Clinical Pharmacology of Erythroid Maturation Pathway Regulators
4.
Precision Medicine for Bone Marrow Microenvironment Remodeling
5.
Everything You Need to Know About HTLV: A Comprehensive Guide
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
2.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge